SCHEMBL6583848

SCHEMBL6583848

Nc1cccc(Nc2ncnc(Nc3cccc(Cl)c3)n2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.64
EGFR P00533 7/20 0.57
ERBB2 P04626 1/20 0.57
SYK P43405 2/20 0.56
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HTR3E A5X5Y0 1/20 0.51
HTR3B O95264 1/20 0.51
HTR3A P46098 1/20 0.51
ROCK1 Q13464 1/20 0.51
HTR3D Q70Z44 1/20 0.51
HTR3C Q8WXA8 1/20 0.51
TTBK1 Q5TCY1 1/20 0.51
TTBK2 Q6IQ55 1/20 0.51
ABL1 P00519 2/20 0.50
CDK1 P06493 1/20 0.50
PRKCA P17252 1/20 0.50
FADS1 O60427 1/20 0.50
BCR P11274 1/20 0.50
SRC P12931 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11584735 0.91 SYK (0.62) CAMK2DEGFRSYKGAAMAPT
SCHEMBL28583340 0.86 ADORA3 (0.67) CAMK2DEGFRERBB2SYKGAA
SCHEMBL21496120 0.86 BCL6 (0.65) CAMK2DEGFRSYKGAAMAPT
SCHEMBL21496110 0.83 SYK (0.55) EGFRSYKGAAMAPTABL1
SCHEMBL21496108 0.83 BCL6 (0.70) EGFRSYKGAAMAPTABL1
SCHEMBL4947229 0.83 SYK (0.56) CAMK2DEGFRSYKGAAMAPT
SCHEMBL6485380 0.81 CAMK2D (0.48) CAMK2DEGFRERBB2SYKGAA
SCHEMBL11795454 0.80 MEN1 (0.63) CAMK2DEGFRSYKGAAMAPT
SCHEMBL31302305 0.80 MEN1 (0.63) CAMK2DEGFRSYKGAAMAPT
SCHEMBL21496113 0.79 SYK (0.51) CAMK2DEGFRSYKGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390354-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS Amgen Inc. (US) 2004-02-25 EP claimed
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. 2003-07-24 US claimed
WO-2002083653-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS AMGEN INC. (US) 2002-10-24 WO claimed
EP-1390354-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS Amgen Inc. (US) 2004-02-25 EP disclosed
WO-2002083653-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use PKD1, PKD2, GLS CAMK2D 3079/4885EGFR 228/4885ERBB2 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.